comparemela.com

Latest Breaking News On - Dato dxd - Page 1 : comparemela.com

FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Expert Perspectives on the Latest TROPION-Lung01 Data

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.